Talquetamab with Iberdomide

A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
38 patients (estimated)
Sponsors
University of California San Francisco
Collaborators
Bristol Myers Squibb, Janssen Research & Development LLC, Bristol Myers Squibb, Janssen Research & Development LLC
Tags
Bispecific Antibody, CD3, GPRC5D
Trial Type
Treatment
Last Update
2 days ago
SparkCures ID
1877
NCT Identifier
NCT06348108

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.